Does the media refer more to CGEN or CADL?

In the previous week, Candel Therapeutics had 8 more articles in the media than Compugen. MarketBeat recorded 9 mentions for Candel Therapeutics and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Candel Therapeutics' score of -0.07 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CYRX or CGEN?

CryoPort has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $182.94M 4.27 $78.30M $1.35 11.47 Compugen $72.76M 2.96 $35.34M $0.37 6.16

Is CYRX or CGEN more profitable?

Compugen has a net margin of 47.97% compared to CryoPort's net margin of 41.57%. Compugen's return on equity of 47.72% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Compugen 47.97% 47.72% 27.51%

Does the media favor CYRX or CGEN?

In the previous week, CryoPort and CryoPort both had 1 articles in the media. Compugen's average media sentiment score of 0.75 beat CryoPort's score of 0.00 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CGEN or OCS?

Compugen has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $72.76M 2.96 $35.34M $0.37 6.16 Oculis $1.45M 564.61 -$119.44M -$2.13 N/A

Is CGEN or OCS more profitable?

Compugen has a net margin of 47.97% compared to Oculis' net margin of -8,460.67%. Compugen's return on equity of 47.72% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.97% 47.72% 27.51% Oculis -8,460.67% -56.78% -45.62%

Does the media prefer CGEN or OCS?

In the previous week, Oculis had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Oculis and 1 mentions for Compugen. Oculis' average media sentiment score of 1.24 beat Compugen's score of 0.75 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, IVA or CGEN?

Compugen has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 160.19 -$400.67M N/A N/A Compugen $72.76M 2.96 $35.34M $0.37 6.16

Is IVA or CGEN more profitable?

Compugen has a net margin of 47.97% compared to Inventiva's net margin of 0.00%. Compugen's return on equity of 47.72% beat Inventiva's return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Compugen 47.97% 47.72% 27.51%

Does the media favor IVA or CGEN?

In the previous week, Inventiva had 2 more articles in the media than Compugen. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Inventiva's score of 0.23 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compugen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compugen (CGEN) Competitors

$2.28 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.28 0.00 (-0.18%)

As of 07/2/2026 07:55 PM Eastern

Compare

CGEN vs. ESPR, CADL, CYRX, OCS, and IVA

Should you buy Compugen stock or one of its competitors? MarketBeat compares Compugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compugen include Esperion Therapeutics (ESPR), Candel Therapeutics (CADL), CryoPort (CYRX), Oculis (OCS), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.

How does Compugen compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Esperion Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 1.6% of Esperion Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Esperion Therapeutics presently has a consensus target price of $5.54, suggesting a potential upside of 75.32%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 119.30%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has a net margin of 47.97% compared to Esperion Therapeutics' net margin of 0.12%. Compugen's return on equity of 47.72% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Compugen	47.97%	47.72%	27.51%

Compugen has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.02	-$22.68M	-$0.06	N/A
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16

In the previous week, Compugen had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 1 mentions for Compugen and 0 mentions for Esperion Therapeutics. Compugen's average media sentiment score of 0.75 beat Esperion Therapeutics' score of 0.00 indicating that Compugen is being referred to more favorably in the news media.

Company	Overall Sentiment
Esperion Therapeutics	Neutral
Compugen	Positive

Summary

Compugen beats Esperion Therapeutics on 15 of the 17 factors compared between the two stocks.

How does Compugen compare to Candel Therapeutics?

Compugen (NASDAQ:CGEN) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 119.30%. Candel Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 83.11%. Given Compugen's stronger consensus rating and higher probable upside, equities analysts plainly believe Compugen is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Compugen has a net margin of 47.97% compared to Candel Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Candel Therapeutics	N/A	-60.42%	-41.33%

Compugen has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the broader market.

In the previous week, Candel Therapeutics had 8 more articles in the media than Compugen. MarketBeat recorded 9 mentions for Candel Therapeutics and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Candel Therapeutics' score of -0.07 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

12.2% of Compugen shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compugen has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Summary

Compugen beats Candel Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Compugen compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Compugen (NASDAQ:CGEN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

CryoPort has higher revenue and earnings than Compugen. Compugen is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$182.94M	4.27	$78.30M	$1.35	11.47
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16

92.9% of CryoPort shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 10.0% of CryoPort shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CryoPort has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Compugen has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

CryoPort currently has a consensus target price of $15.11, indicating a potential downside of 2.45%. Compugen has a consensus target price of $5.00, indicating a potential upside of 119.30%. Given Compugen's higher probable upside, analysts plainly believe Compugen is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has a net margin of 47.97% compared to CryoPort's net margin of 41.57%. Compugen's return on equity of 47.72% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Compugen	47.97%	47.72%	27.51%

In the previous week, CryoPort and CryoPort both had 1 articles in the media. Compugen's average media sentiment score of 0.75 beat CryoPort's score of 0.00 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CryoPort beats Compugen on 8 of the 15 factors compared between the two stocks.

How does Compugen compare to Oculis?

Compugen (NASDAQ:CGEN) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Compugen has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A

Compugen has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

12.2% of Compugen shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Compugen has a net margin of 47.97% compared to Oculis' net margin of -8,460.67%. Compugen's return on equity of 47.72% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Oculis	-8,460.67%	-56.78%	-45.62%

In the previous week, Oculis had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for Oculis and 1 mentions for Compugen. Oculis' average media sentiment score of 1.24 beat Compugen's score of 0.75 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen currently has a consensus target price of $5.00, indicating a potential upside of 119.30%. Oculis has a consensus target price of $38.33, indicating a potential upside of 171.48%. Given Oculis' higher probable upside, analysts plainly believe Oculis is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Compugen beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Compugen compare to Inventiva?

Inventiva (NASDAQ:IVA) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Inventiva has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Compugen has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market.

Compugen has a net margin of 47.97% compared to Inventiva's net margin of 0.00%. Compugen's return on equity of 47.72% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Compugen	47.97%	47.72%	27.51%

19.1% of Inventiva shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Inventiva had 2 more articles in the media than Compugen. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Compugen. Compugen's average media sentiment score of 0.75 beat Inventiva's score of 0.23 indicating that Compugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	160.19	-$400.67M	N/A	N/A
Compugen	$72.76M	2.96	$35.34M	$0.37	6.16

Inventiva currently has a consensus price target of $16.56, suggesting a potential upside of 323.42%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 119.30%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Inventiva beats Compugen on 8 of the 15 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.58M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	6.16	21.61	28.02	24.70
Price / Sales	2.96	340.19	540.37	99.49
Price / Cash	6.10	147.12	49.26	57.09
Price / Book	2.09	8.66	10.96	6.46
Net Income	$35.34M	$23.81M	$3.57B	$337.01M
7 Day Performance	8.83%	3.39%	2.12%	1.69%
1 Month Performance	8.57%	10.81%	5.25%	3.81%
1 Year Performance	28.09%	62.61%	33.29%	23.90%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	3.7975 of 5 stars	$2.28 flat	$5.00 +119.3%	+28.1%	$215.58M	$72.76M	6.16	70	Gap Down
ESPR Esperion Therapeutics	2.1395 of 5 stars	$3.16 +0.2%	$5.54 +75.6%	+169.9%	$813.01M	$403.14M	N/A	200
CADL Candel Therapeutics	2.6362 of 5 stars	$11.01 +6.2%	$18.00 +63.6%	+92.7%	$801.94M	N/A	N/A	60	News Coverage Insider Trade
CYRX CryoPort	2.9392 of 5 stars	$15.65 -3.9%	$15.11 -3.4%	+102.7%	$788.76M	$176.18M	11.59	1,186	Positive News
OCS Oculis	3.5463 of 5 stars	$13.37 +2.1%	$38.33 +186.7%	-25.5%	$774.32M	$1.45M	N/A	2	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. ESPR, CADL, CYRX, OCS, and IVA

How does Compugen compare to Esperion Therapeutics?

Summary

How does Compugen compare to Candel Therapeutics?

Summary

How does Compugen compare to CryoPort?

Summary

How does Compugen compare to Oculis?

Summary

How does Compugen compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. ESPR, CADL, CYRX, OCS, and IVA

How does Compugen compare to Esperion Therapeutics?

Which has more risk & volatility, ESPR or CGEN?

Do institutionals and insiders hold more shares of ESPR or CGEN?

Do analysts recommend ESPR or CGEN?

Is ESPR or CGEN more profitable?

Which has higher earnings and valuation, ESPR or CGEN?

Does the media favor ESPR or CGEN?

Summary

How does Compugen compare to Candel Therapeutics?

Do analysts rate CGEN or CADL?

Is CGEN or CADL more profitable?

Which has more volatility & risk, CGEN or CADL?

Does the media refer more to CGEN or CADL?

Do insiders & institutionals hold more shares of CGEN or CADL?

Which has better earnings and valuation, CGEN or CADL?

Summary

How does Compugen compare to CryoPort?

Which has higher earnings & valuation, CYRX or CGEN?

Do institutionals & insiders believe in CYRX or CGEN?

Which has more volatility & risk, CYRX or CGEN?

Do analysts prefer CYRX or CGEN?

Is CYRX or CGEN more profitable?

Does the media favor CYRX or CGEN?

Summary

How does Compugen compare to Oculis?

Which has higher valuation and earnings, CGEN or OCS?

Which has more volatility and risk, CGEN or OCS?

Do insiders and institutionals hold more shares of CGEN or OCS?

Is CGEN or OCS more profitable?

Does the media prefer CGEN or OCS?

Do analysts recommend CGEN or OCS?

Summary

How does Compugen compare to Inventiva?

Which has more volatility & risk, IVA or CGEN?

Is IVA or CGEN more profitable?

Do institutionals and insiders have more ownership in IVA or CGEN?

Does the media favor IVA or CGEN?

Which has preferable earnings and valuation, IVA or CGEN?

Do analysts recommend IVA or CGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools